172 related articles for article (PubMed ID: 33847193)
21. Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
De Laurentiis M; Borstnar S; Campone M; Warner E; Bofill JS; Jacot W; Dent S; Martin M; Ring A; Cottu P; Lu J; Ciruelos E; Azim HA; Chatterjee S; Zhou K; Wu J; Menon-Singh L; Zamagni C
Breast Cancer Res Treat; 2021 Oct; 189(3):689-699. PubMed ID: 34414532
[TBL] [Abstract][Full Text] [Related]
22. Association between ribociclib and changes in creatinine in patients with hormone receptor positive metastatic breast cancer.
Wilson BE; Mok K; Kiely BE; Nguyen R; Moylan E
Intern Med J; 2019 Nov; 49(11):1438-1442. PubMed ID: 31713335
[TBL] [Abstract][Full Text] [Related]
23. Ribociclib-induced visual hallucination in a patient with metastatic breast cancer.
Kapagan T; Bulut N; Demirer S; Erdem GU
J Oncol Pharm Pract; 2023 Sep; 29(6):1529-1532. PubMed ID: 37306182
[TBL] [Abstract][Full Text] [Related]
24. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
25. Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
Verma S; O'Shaughnessy J; Burris HA; Campone M; Alba E; Chandiwana D; Dalal AA; Sutradhar S; Monaco M; Janni W
Breast Cancer Res Treat; 2018 Aug; 170(3):535-545. PubMed ID: 29654415
[TBL] [Abstract][Full Text] [Related]
26. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
27. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
Slamon DJ; Neven P; Chia S; Jerusalem G; De Laurentiis M; Im S; Petrakova K; Valeria Bianchi G; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Ji Y; Wang C; Deore U; Chakravartty A; Zarate JP; Taran T; Fasching PA
Ann Oncol; 2021 Aug; 32(8):1015-1024. PubMed ID: 34102253
[TBL] [Abstract][Full Text] [Related]
28. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; de Groot S; Riemsma R; Fayter D; Armstrong N; Portegijs P; Duffy S; Kleijnen J; Al MJ
Pharmacoeconomics; 2019 Feb; 37(2):141-153. PubMed ID: 30194622
[TBL] [Abstract][Full Text] [Related]
29. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
Slamon DJ; Neven P; Chia S; Fasching PA; De Laurentiis M; Im SA; Petrakova K; Bianchi GV; Esteva FJ; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Pivot X; Vidam G; Wang Y; Rodriguez Lorenc K; Miller M; Taran T; Jerusalem G
J Clin Oncol; 2018 Aug; 36(24):2465-2472. PubMed ID: 29860922
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.
Curigliano G; Criscitiello C; Esposito A; Intra M; Minucci S
Expert Opin Drug Metab Toxicol; 2017 May; 13(5):575-581. PubMed ID: 28395543
[TBL] [Abstract][Full Text] [Related]
31. CDK 4/6 inhibitor successful rechallenge after limiting hepatic toxicity.
Meynard L; Grellety T
Breast J; 2020 Feb; 26(2):255-257. PubMed ID: 31495008
[TBL] [Abstract][Full Text] [Related]
32. Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2- metastatic breast cancer.
Kristensen KB; Thomsen IMN; Berg T; Kodahl AR; Jensen AB
Breast Cancer Res Treat; 2021 Aug; 188(3):799-809. PubMed ID: 33837869
[TBL] [Abstract][Full Text] [Related]
33. Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials.
Sanò MV; Martorana F; Lavenia G; Rossello R; Prestifilippo A; Sava S; Ricciardi GR; Vigneri P
Expert Rev Anticancer Ther; 2022 Apr; 22(4):343-351. PubMed ID: 35303782
[TBL] [Abstract][Full Text] [Related]
34. Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Zangardi ML; Spring LM; Blouin GC; Bardia A
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1169-1176. PubMed ID: 28875723
[TBL] [Abstract][Full Text] [Related]
35. Vortex keratopathy associated with ribociclib.
Türkel A; Özdoğan S; Yekedüz E; Şeyran E; Karaçin C; Ateş Ö
J Oncol Pharm Pract; 2023 Jan; 29(1):230-232. PubMed ID: 35570741
[TBL] [Abstract][Full Text] [Related]
36. A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer.
Topcu A; Yasin AI; Shbair AT; Besiroglu M; Simsek M; Sucuoglu Z; Yurtsever I; Gucin Z; Seker M; Turk HM
J Oncol Pharm Pract; 2022 Jan; 28(1):242-246. PubMed ID: 34162247
[TBL] [Abstract][Full Text] [Related]
37. Ribociclib Lengthens Breast Cancer Survival.
Cancer Discov; 2016 Dec; 6(12):1299. PubMed ID: 27810861
[TBL] [Abstract][Full Text] [Related]
38. Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient.
Farhat F; Tarabaih M; Kanj A; Aoun M; Kattan J; Assi T; Awada A
Anticancer Drugs; 2020 Jan; 31(1):85-89. PubMed ID: 31609762
[TBL] [Abstract][Full Text] [Related]
39. Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer.
Ji Y; Schiller H; Yang S; Quinlan M; Darstein C; Huth F; Winter S; Chakraborty A
Clin Pharmacokinet; 2024 Feb; 63(2):155-170. PubMed ID: 38244190
[TBL] [Abstract][Full Text] [Related]
40. Ribociclib mitigates cisplatin-associated kidney injury through retinoblastoma-1 dependent mechanisms.
Kim JY; Jayne LA; Bai Y; Feng MJHH; Clark MA; Chung S; W Christman J; Cianciolo RE; Pabla NS
Biochem Pharmacol; 2020 Jul; 177():113939. PubMed ID: 32229099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
